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Abstract—Diabetes is a debilitating metabolic disorder 
resulting from hyperglycemia and glucose intolerance. High 
glucose-induced endothelial dysfunction is an important 
contributor to vascular disease in diabetes. In this study, we 
profiled the global gene expression changes in human umbilical 
vein endothelial cells treated with high glucose at the 0-, 24-, and 
48-hour intervals. Differentially expressed genes were examined 
through bioinformatics analysis for potential mechanisms of 
regulation. Our analysis uncovered novel regulatory interactions 
that may provide insights into the molecular transition from 
normal cellular activities to apoptosis under high glucose, 
enhancing our understanding of the mechanisms underlying 
vascular complications in diabetic patients. 
Keywords—high glucose, gene expression, diabetes, time-
course analysis 
I.  INTRODUCTION 
Diabetes mellitus is the major contributor of high glucose-
induced endothelial dysfunction—an important pathogenic 
factor of vascular complications in diabetic patients [1]. The 
endothelium plays a prominent role in vascular homeostasis. 
Substantial evidence suggests that elevated glucose 
concentrations increase the production of reactive oxygen 
species, inducing endothelial apoptosis, and upsetting the 
balance between cell repair and injury [2, 3]. 
To date, several cellular pathways have been found to 
mediate the effect of high glucose on endothelial dysfunction. 
Hyperglycemia causes dysregulation of the mitochondria, 
increasing oxidative stress through the activation of the polyol 
pathway [4], diacylglycerol-protein kinase C pathway [5], and 
hexoamine pathway [6]. Not only does hyperglycemia result in 
the overproduction of reactive oxygen species in endothelial 
cells, but it also contributes to the formation of advanced 
glycation end-products (AGE) [7, 8]. AGE crosslinks with 
tissue proteins, lipids, and DNA, affecting their functions and 
turnover, contributing to a decline in endothelial function, and 
ultimately, diabetic vascular complications [7]. 
Until recently, the effect of high glucose on gene 
expression has only been profiled at the single gene/pathway 
level [9-11]. Pirola et al. [12] has examined the effect of 
endothelial apoptosis under hyperglycemia at both the 
transcriptomic and epigenomic levels. Their findings present 
the first global picture of hyperglycemia-induced gene 
expression changes occurring through histone modifications 
and differences in DNA methylation. This particular study has 
shown that the process of apoptosis during high glucose 
exposure is complex, involving various levels of molecular 
control. Their results bring to question the mechanisms 
underlying the transition of normal cellular activities to 
hyperglycemia-induced cell death. In other words, what are the 
key players controlling the progress towards apoptosis during 
high glucose treatment. If we could reach the answers, would 
we be able to find effective ways to enhance the protection 
against cell death before it occurs? Apparently, there are still 
questions that remain to be answered. 
Over the years of studying diabetes mellitus, we have 
learned that cell death start to occur around 36 hours after 
treatment with high glucose [10]. In this study, we performed a 
time-course gene expression array study examining 
hyperglycemia-induced transcriptome changes during epithelial 
cell death. We attempted to identify the underlying genetic key 
players before and during apoptosis under high glucose. The 
finding is particularly invaluable to the future development of 
treatment for chronic diabetic complications. 
II. MATERIALS AND METHODS 
A. Cell culture and treatment  
Growing and maintaining of human umbilical vein 
endothelial cells (HUVECs) were as described in [13] and cells 
were seeded at a density of 1 x 105 per 75-cm2-flask medium 
199 (Gibco, Grand Island, New York), supplemented with 20 
mM HEPES, 100 ug/ml endothelial cell growth substance 
(Collaborative Research Inc, Bedford, MA), and 20% fetal calf 
serum (Gibco). The cultures were maintained at 37°C with 
5%CO2-95% air mixture. All media were supplemented with 5 
U/ml heparin, 100 IU/ml penicillin, and 0.1 Ag/ml 
streptomycin. Treatment of glucose followed Ho et al., 2006. 
Briefly, endothelial cells of the third to fifth passages in 
actively growing condition were harvested fand treated with a 
medium containing 5 mM glucose for 48 hours (basal glucose; 
control, n=3) or 33 mM glucose (high glucose; experimental) 
for different time intervals (24 hours, n=3; 48 hours, n=3).  
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B. Detection of apoptosis  
Apoptosis of treated HUVECs were detected by the ELISA 
method of cell death (Boheringer Mannheim) and assessed for 
morphological changes under a fluorescence microscope. 
Intracellular hydrogen peroxide production was measured by 
flow cytometry analysis. 
C. RNA isolation  
The control and experimental treatments were conducted in 
duplicates. RNA was isolated by Trizol (Invitrogen, Carlsbad, 
California, USA). RNA quality was determined by a 260/280 
ratio of 1.9-2.1 on a spectrophotometer and by the intensity of 
the 18S and 28S rRNA bands on a 1% formaldehyde-agarose 
gel. RNA quantity was detected by a spectrophotometer. RNA 
integrity was examined on an Agilent Bioanalyzer. 
D. Array-based gene expression profiling  
Global gene expression changes associated with high 
glucose exposure at different time intervals were profiled on 
Nimblegen human gene expression 12x135k array. Each 
sample was run in duplicates. 
E. Statistical and Bioinformatics Analysis 
To identify genes showing significant differential 
expression associated with the differing glucose treatments and 
time intervals, gene expression profiles at the 24-hour and 48-
hour intervals were first normalized to the control (basal 
glucose treatment for 48 hours). Data were processed with 
R/Bioconductor. Significantly differentially expressed genes 
(absolute value of log2 ratio > 1.0, FDR <0.05) were 
categorized into 24-hour- and 48-hour- specific down- and up-
regulated genes. These genes were subsequently used as input 
in the PANTHER classification system for gene ontology (GO) 
enrichment analysis [14].  
We employed the features in TRANSFAC [15] and 
miRWalk [13] to find transcription factors and miRNAs that 
may regulate the candidate genes, respectively. The cross-
validation function in miRWalk was used to compare the 
prediction results with four other miRNA resources: miRanda 
[16], miRDB [17], RNA22 [18], and TargetScan [19]. A 
predicted miRNA was accepted as a potential regulatory 
candidate when four out of the five miRNA resources agreed 
that it may interact with the differentially expressed genes. 
Finally, we utilized the tools in BIOGRAPH to determine if the 
differentially expressed genes are associated with diabetes or 
correlated complications [20].  
III. RESULTS AND DISCUSSIONS 
In total, there are 93 up-regulated and 207 down-regulated 
genes, and 57 up-regulated and 17 down-regulated genes 
specific to the 24-hour and 48-hour interval, respectively. At 
both time points, the top three most enriched pathways 
appeared to be angiogenesis, apoptosis, and inflammation. 
Table I shows a partial list of genes belonging to these three 
categories. These genes are selected based on their association 
with diabetes and cardiovascular dysfunction according to 
BIOGRAPH analysis.  
Many of the genes involved in the regulation of cell death 
and inflammation have already been identified by others. This 
shows that our results are consistent with others. In contrast, 
abnormal angiogenesis, or the impaired formation of new 
TABLE I.  A LIST OF SELECTED GENES IN THE ENRICHED PATHWAYS 
THAT ARE ALSO ASSOCIATED WITH DIABETES AND CARDIOVASCULAR 
COMPLICATIONS 
Pathway 24-hour 48-hour 
Angiogenesis AKT2 AKT2 
 PTHN6 STAT3 
Apoptosis AKT2 AKT2 
 HSPA6 RAC3 
 ATF7 STAT3 
 MYCL1 RPS6KB2 
Inflammation JAK3 RAC3 
 CD14 STAT3 
 
blood cells from pre-existing blood vessels, has only recently 
been found to cause various complications involving the retina, 
kidney, and cardiovascular system [21].  
Table II shows a partial list of transcription factors that may 
regulate the differentially expressed genes as predicted by 
TRANSFAC. Some In particular, the AKT2 gene (v-akt 
murine thymoma viral oncogene homolog 2) appears to be 
differentially expressed at both investigated time points. The 
level of AKT2 expression is reduced at the 24-hour time point 
and subsequently increased at the 48-hour interval. AKT2 is 
involved in angiogenesis, anti-apoptotic activity and 
inflammatory response [22]. Moreover, a rare mutation in the 
AKT2 gene sequence has been associated with severe insulin 
resistance and diabetes [23].  
Our results support that the AKT2 gene may also play a 
role in diabetes-associated vascular complications. Indeed, 
exposure to high concentrations of glucose can induce 
apoptosis in endothelial cells [7, 8], and AKT2 is known to 
enhance the expression of anti-apoptotic proteins during cell 
death [24]. That we observed a time-specific change in AKT2 
expression level indicates that AKT2 gene expression may be 
under temporal regulation during a high glucose challenge. We 
furthered this finding with bioinformatics analysis of the 
possible regulatory mechanisms of the AKT2 expression.  
TABLE II.  A PARTIAL LIST OF POTENTIAL TRANSCRIPTION FACTORS 
REGULATING DIFFERENTIALLY EXPRESSED GENES UNDER HIGH GLUCOSE 
EXPOSURE 
 gene expression transcription factor 
24 hour  AKT2 up MYOD 
 ATP2A3 up ETS-1 
 CYP1B1 up ER-α 
 CD14 down SP1 
 IGFBP6 down GLI 
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 gene expression transcription factor 
48 hour ADM up AP-2α 
 CDK5 down AP-1 
 STAT3 down CREB1 
 
According to TRANSFAC [15], MYOD (myogenic 
differentiation 1) acts as an enhancer for AKT2. Interestingly, 
our data indicate that MYOD and AKT2 share the same 
expression pattern in response to the 24-hour high glucose 
treatment. However, MYOD expression level after 48 hours of 
hyperglycemia did not appear to differ significantly from the 
24-hour time point. This suggests that other regulatory 
mechanisms may be regulating AKT2 expression at the 48-
hour interval.  
To search for additional regulatory molecules, we utilized 
the features in mirWalk [13] to find putative microRNAs that 
may modulate the expression of the differentially expressed 
transcripts observed in our data analysis. The microRNA-gene 
interactions are selected based on experimentally validated 
relationships between the two biomolecules, and the 
association of these microRNAs with diabetes and related 
complications. An example of our analytical results is 
illustrated in Fig.1. The putative regulatory microRNAs 
connecting the genes AKT2 and CYP1B1 (Cytochrome P450, 
Family 1, Subfamily B, Polypeptide 1) may represent another 
potential mechanism underlying hyperglycermia-induced 
apoptosis. In particular, microRNAs may reveal different 
molecular signatures that are not apparent in gene expression 
profiling.  
In conclusion, we have uncovered a number of 
differentially expressed genes associated with the transition 
from normal cellular activities to apoptosis during high glucose 
exposure. Our findings are consistent with other studies in that 
many of the candidate genes are involved in apoptosis and 
inflammatory pathways. However, we have identified genes 
that show temporal gene expression patterns under high 
glucose condition. Moreover, by integrating available 
bioinformatics tools, we have attempted to construct a map of 
the potential regulatory mechanisms involving transcription 
factors and microRNAs modulating these candidate genes. 
Future validation of these preliminary results shall enhance our 
understanding of the molecular underpinnings of endothelial 
cell apoptosis induced by high glucose, and therefore, diabetes 
associated vascular dysfunction. 
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